BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 27690272)

  • 1. Considerations for successful cancer immunotherapy in aged hosts.
    Hurez V; Padrón ÁS; Svatek RS; Curiel TJ
    Clin Exp Immunol; 2017 Jan; 187(1):53-63. PubMed ID: 27690272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for successful cancer immunotherapy in aged hosts.
    Hurez V; Padrón Á; Svatek RS; Curiel TJ
    Exp Gerontol; 2018 Jul; 107():27-36. PubMed ID: 28987644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
    Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
    Front Immunol; 2018; 9():1288. PubMed ID: 29915603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?
    Jackaman C; Nelson DJ
    Exp Gerontol; 2014 Jun; 54():53-7. PubMed ID: 24291067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of T cells by myeloid-derived suppressor cells in cancer.
    Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
    Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.
    Stahl M; Gedrich R; Peck R; LaVallee T; Eder JP
    Immunotherapy; 2016 Jun; 8(7):767-74. PubMed ID: 27349976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations and Approaches for Cancer Immunotherapy in the Aging Host.
    Ontiveros CO; Murray CE; Crossland G; Curiel TJ
    Cancer Immunol Res; 2023 Nov; 11(11):1449-1461. PubMed ID: 37769157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.
    Tuettenberg A; Steinbrink K; Schuppan D
    Nanomedicine (Lond); 2016 Oct; 11(20):2735-2751. PubMed ID: 27658725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-derived suppressor cells: Multi-talented immune suppressive cells that can be either helpful or harmful.
    Cell Immunol; 2021 Jul; 365():104374. PubMed ID: 34038759
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunosenescence and cancer.
    Pawelec G
    Biogerontology; 2017 Aug; 18(4):717-721. PubMed ID: 28220304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosenescence: a key player in cancer development.
    Lian J; Yue Y; Yu W; Zhang Y
    J Hematol Oncol; 2020 Nov; 13(1):151. PubMed ID: 33168037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From cancer immunosurveillance to cancer immunotherapy.
    Stagg J; Johnstone RW; Smyth MJ
    Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncology meets immunology: the cancer-immunity cycle.
    Chen DS; Mellman I
    Immunity; 2013 Jul; 39(1):1-10. PubMed ID: 23890059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDSC; the Most Important Cell You Have Never Heard Of.
    Tesi RJ
    Trends Pharmacol Sci; 2019 Jan; 40(1):4-7. PubMed ID: 30527590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of immune evasion in breast cancer.
    Bates JP; Derakhshandeh R; Jones L; Webb TJ
    BMC Cancer; 2018 May; 18(1):556. PubMed ID: 29751789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.
    Kalathil SG; Thanavala Y
    Cancer Immunol Immunother; 2016 Jul; 65(7):813-9. PubMed ID: 26910314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate myeloid cells in the tumor microenvironment.
    Duhan V; Smyth MJ
    Curr Opin Immunol; 2021 Apr; 69():18-28. PubMed ID: 33588308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophils in cancer.
    Treffers LW; Hiemstra IH; Kuijpers TW; van den Berg TK; Matlung HL
    Immunol Rev; 2016 Sep; 273(1):312-28. PubMed ID: 27558343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curdlan blocks the immune suppression by myeloid-derived suppressor cells and reduces tumor burden.
    Rui K; Tian J; Tang X; Ma J; Xu P; Tian X; Wang Y; Xu H; Lu L; Wang S
    Immunol Res; 2016 Aug; 64(4):931-9. PubMed ID: 26832917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects.
    Hwang I; Nguyen N
    Arch Pharm Res; 2015 Aug; 38(8):1415-33. PubMed ID: 25634101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.